Formation of disulfide bridges drives oligomerization, membrane pore formation, and translocation of fibroblast growth factor 2 to cell surfaces.

Fibroblast growth factor 2 (FGF2) is a key signaling molecule in tumor-induced angiogenesis. FGF2 is secreted by an unconventional secretory mechanism that involves phosphatidylinositol 4,5-bisphosphate-dependent insertion of FGF2 oligomers into the plasma membrane. This process is regulated by Tec kinase-mediated tyrosine phosphorylation of FGF2.

Operation Bali assist--the Royal Darwin Hospital Intensive Care Unit.

On October 12, 2002 the Bali bombing resulted in 62 severely injured patients being evacuated to Royal Darwin Hospital. This paper describes the planning and execution of the Intensive Care Unit disaster plan in the wake of the Bali bombing. There were a total of 20 patients from the Bali blast admitted to the Intensive Care Unit.

[The dose-dependent effects of oral premedication with midazolam].

Objective: The aim of this study was to examine the psychological effects, well-being and side effects after various doses of oral midazolam medication.

Methods: After informed consent has been obtained and following the approval by the institutional ethical committee, 80 adult patients in the ASA physical status I and II were randomly assigned to one of five different premedication groups: 3.75, 7.

Orofacial features of Scheie (Hurler-Scheie) syndrome (alpha-L-iduronidase deficiency).

Scheie syndrome is a rare inborn error of metabolism, a mucopolysaccharidosis in which deficiency of the lysosomal enzyme alpha-L-iduronidase leads to tissue accumulation of mucopolysaccharides. Scheie syndrome is a forme fruste of Hurler syndrome (gargoylism), and some patients have the phenotype of Hurler-Scheie compound syndrome. The craniofacial abnormalities include coarse facies, mandibular condylar hypoplasia, retarded tooth eruption, and cystic jaw radiolucencies--particularly about the molars.

One-dose treatment of acute uncomplicated gonorrhoea of male patients with ceftriaxone Ro 13-9904, a new parenteral cephalosporin. A dose-range finding pilot study using doses of 500, 250, 125 and 50 mg respectively, in descending order.

54 adult male patients suffering from acute uncomplicated gonococcal urethritis entered a dose-range trial with a new parenteral cephalosporin, ceftriaxone Ro 13-9904. In order to evaluate the lowest effective dose of a single intramuscular injection of Ro 13-9904, the patients received different doses in descending order: 500 mg for the first group of 10 patients, 250 mg for the second group of 13 patients, 125 mg for the third group of 11 patients and 50 mg for the fourth group of 20 patients. All 34 patients of the first three trial groups were cured clinically and bacteriologically.